SAB Biotherapeutics (NASDAQ:SABS) Issues Earnings Results, Beats Estimates By $0.03 EPS

SAB Biotherapeutics (NASDAQ:SABS) announced its quarterly earnings data on Thursday. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.03, FiscalAI reports.

Here are the key takeaways from SAB Biotherapeutics’ conference call:

• SAFEGUARD enrollment is progressing: adult and adolescent cohorts are fully enrolled and closed to screening, and SAB Bio expects to complete enrollment in Q4 2026. Top-line data are expected in the second half of 2027.
• The FDA granted Fast Track designation to SAB-142, which may allow more frequent FDA interactions and rolling review of a future BLA; the designation does not guarantee approval or change the approval standard.
• The investigator-led PRISE study expects to dose its first patient in Q4 2026 and will evaluate SAB-142 in patients diagnosed up to two years earlier. Management sees the study as a potential path to expanding the eligible population, but did not provide a data timeline.
• SAB Bio reported $205 million in cash, cash equivalents and investment securities at quarter-end and said its cash should fund operations through 2028, including the planned PRISE expenses.
• Quarterly R&D and G&A expenses rose to $18.1 million and $7.8 million, respectively, as the company advanced its clinical program; SAB Bio reported a $22.3 million net loss versus net income a year earlier, when results included a large warrant-liability fair-value gain.

SAB Biotherapeutics Stock Up 3.1%

Shares of SABS stock traded up $0.09 on Friday, hitting $3.03. The company’s stock had a trading volume of 300,599 shares, compared to its average volume of 666,437. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.22 and a quick ratio of 9.22. SAB Biotherapeutics has a fifty-two week low of $2.44 and a fifty-two week high of $5.15. The firm’s fifty day moving average price is $3.19 and its 200-day moving average price is $3.66. The stock has a market capitalization of $275.70 million, a price-to-earnings ratio of -2.28 and a beta of 0.67.

Wall Street Analyst Weigh In

SABS has been the subject of several recent research reports. Wall Street Zen upgraded SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, August 10th. Weiss Ratings raised SAB Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $12.00.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a biotechnology company focused on developing fully human polyclonal antibody medicines for infectious diseases, immune disorders and other conditions where targeted immune responses may provide therapeutic benefits. The company is based in Sioux Falls, South Dakota.

SAB Biotherapeutics uses its DiversitAb platform, which involves genetically engineered cattle capable of producing antibodies with human immune-system characteristics. Antibodies are collected from the animals’ plasma and processed for potential use as treatments, allowing the company to pursue antibody products without relying solely on conventional human donor sources.

The company has developed a pipeline that has included SAB-185, an investigational antibody therapy directed at SARS-CoV-2, as well as programs targeting influenza and autoimmune or immune-mediated diseases.